UCSF and Northwestern Awarded $4.2M to Advance Glioblastoma Therapeutics

Glioblastoma is the most common malignant brain tumor and among the most treatment-resistant cancers. In the last 15 years, numerous attempts to develop new drugs for glioblastoma have failed. In response, the National Cancer Institute (NCI) has established the Glioblastoma Therapeutics Network (GTN

An Estrogen Receptor that Promotes Cancer also Causes Drug Resistance

Cancer cells proliferate despite a myriad of stresses – from oxygen deprivation to chemotherapy – that would kill any ordinary cell. Now, researchers at UC San Francisco have gained insight into how they may be doing this through the downstream activity of a powerful estrogen receptor. The discovery

HDFCCC Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials

Cancer Center BOP Members May Boycott Conference over Texas Abortion Law

In response to the recent adoption of the Texas Heartbeat Act (SB8) banning nearly all abortions, the Cancer Center’s Breast Oncology Program members are part of a growing effort to move the annual San Antonio Breast Cancer Symposium (SABCS) out of Texas. The new law, which bans abortions after six

Ana Velázquez Mañana, MD, ASCO Mentor for Oncology Student Diversity

The RIDR Program: Providing Early Career Opportunities for Historically Underrepresented Student Groups

“It is critical that we bring people with diverse perspectives and backgrounds into medicine. Our medical teams must reflect the diversity of our communities in order for patients to have the best possible outcomes,” says Matthew Bucknor, MD, associate chair for wellbeing and professional climate

UCSF Radiology and Radiation Oncology Researchers Join Forces to Study HP 13C MRI in Prostate Cancer Undergoing Radiation Therapy

Two faculty members in the UC San Francisco Department of Radiology and Biomedical Imaging recently received funding from National Institutes of Health (NIH)/National Cancer Institute (NCI) for an exciting research project to study hyperpolarized (HP) carbon-13 (13C) metabolic MRI in prostate cancer